Search Advanced

AIMS Molecular Science

2015, Volume 2, Issue 2: 124-143. doi: 10.3934/molsci.2015.2.124
Previous Article Next Article
Review Special Issues

microRNA as a new agent for regulating neuronal glutathione synthesis and metabolism

  • Department of Pharmacology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan
  • Received: 03 February 2015 Accepted: 09 April 2015 Published: 20 April 2015

  • microRNA (miRNA) is a small non-coding RNA molecule that plays a role in the post-transcriptional regulation of gene expression. Recent evidence shows that miRNAs are involved in various diseases,including neurodegenerative diseases (NDs) such as: Parkinson's disease,Alzheimer's disease,Huntington's disease,Amyotrophic lateral sclerosisand multiple system atrophy (MSA).
    The initiation and progression of NDs is generally considered to be induced by oxidative stress arising from an imbalance of oxidants and antioxidants. One of the most important antioxidants against oxidative stress is glutathione (GSH),which is a tripeptide composed of cysteine,glutamate and glycine. Among these precursor amino acids,cysteine is the determinant of neuronal GSH synthesis. Cysteine uptake in the neurons is mostly mediated by excitatory amino acid carrier 1 (EAAC1),a member of the sodium-dependent excitatory amino acid transporters. Interestingly,it has been reported that one miRNA,miR-96-5p,regulates the neuroprotective effect of GSH by directly regulating EAAC1 expression. Furthermore,the expressions of miR-96-5p and its target EAAC1 are specifically deregulated in the brains of patients with MSA,suggesting that deregulated miR-96-5p induces MSA via EAAC1 down-regulation. Since miR-96-5p regulation of EAAC1 expression and GSH level is indicated to be under circadian control,a greater understanding of rhythmic miRNA regulation could lead to the use of miRNA in chronotherapy for ND.
    In this review,we focus on the role of miRNA in the mechanism of GSH synthesis and metabolism; particularly with respect to a critical transport system of its rate-limiting substrate via EAAC1,as well as on the implications and chronotherapeutic potential of miRNA for NDs.

    Citation: Chisato Kinoshita, Koji Aoyama, Toshio Nakaki. microRNA as a new agent for regulating neuronal glutathione synthesis and metabolism[J]. AIMS Molecular Science, 2015, 2(2): 124-143. doi: 10.3934/molsci.2015.2.124

    Related Papers:

    [1] Moshe Rosenberg, Yael Rosenberg . Proteolysis during aging of commercial full-fat and reduced-fat Cheddar cheeses of identical chronological age. AIMS Agriculture and Food, 2022, 7(4): 855-871. doi: 10.3934/agrfood.2022052
    [2] Emmanuel Hanyabui, Samuel Obeng Apori, Kwame Agyei Frimpong, Kofi Atiah, Thomas Abindaw, Muhammed Ali, Joshua Yeboah Asiamah, John Byalebeka . Phosphorus sorption in tropical soils. AIMS Agriculture and Food, 2020, 5(4): 599-616. doi: 10.3934/agrfood.2020.4.599
    [3] Graciela Ivette Béjar-Lio, Néstor Gutiérrez-Méndez, Guadalupe Virginia Nevárez-Moorillón . Microbiological and physicochemical characteristics of Chihuahua cheese manufactured with raw milk. AIMS Agriculture and Food, 2020, 5(1): 86-101. doi: 10.3934/agrfood.2020.1.86
    [4] Eleni C. Pappa, Efthymia Kondyli, Anna-Maria Vlachou, Athanasia Kakouri, Evdokia Malamou, John Samelis . Semi industrial production of Tsalafouti dairy product. AIMS Agriculture and Food, 2022, 7(2): 444-460. doi: 10.3934/agrfood.2022028
    [5] Aliou Badara Kouyate, Vincent Logah, Robert Clement Abaidoo, Francis Marthy Tetteh, Mensah Bonsu, Sidiki Gabriel Dembélé . Phosphorus sorption characteristics in the Sahel: Estimates from soils in Mali. AIMS Agriculture and Food, 2023, 8(4): 995-1009. doi: 10.3934/agrfood.2023053
    [6] Francisco L. Pérez . Viticultural practices in Jumilla (Murcia, Spain): a case study of agriculture and adaptation to natural landscape processes in a variable and changing climate. AIMS Agriculture and Food, 2016, 1(3): 265-293. doi: 10.3934/agrfood.2016.3.265
    [7] Budi Suarti, Sukarno, Ardiansyah, Slamet Budijanto . Bio-active compounds, their antioxidant activities, and the physicochemical and pasting properties of both pigmented and non-pigmented fermented de-husked rice flour. AIMS Agriculture and Food, 2021, 6(1): 49-64. doi: 10.3934/agrfood.2021004
    [8] Sapta Raharja, Yogi Purna Rahardjo, Samsudin, Khaswar Syamsu . Aroma precursor enhancing in dried cocoa beans fermentation using enzyme and heat addition. AIMS Agriculture and Food, 2023, 8(2): 674-686. doi: 10.3934/agrfood.2023037
    [9] Artyom Lamanov, Yurij Ivanov, Rishat Iskhakov, Liliya Zubairova, Khamit Tagirov, Azat Salikhov . Beef quality indicators and their dependence on keeping technology of bull calves of different genotypes. AIMS Agriculture and Food, 2020, 5(1): 20-29. doi: 10.3934/agrfood.2020.1.20
    [10] Siti Hajar Othman, Nazirah Mohd Rosli, Norhazirah Nordin, Masturina Abdul Aziz . Formulation of crispy chicken burger patty batter: Properties and storage qualities. AIMS Agriculture and Food, 2022, 7(2): 426-443. doi: 10.3934/agrfood.2022027
  • microRNA (miRNA) is a small non-coding RNA molecule that plays a role in the post-transcriptional regulation of gene expression. Recent evidence shows that miRNAs are involved in various diseases,including neurodegenerative diseases (NDs) such as: Parkinson's disease,Alzheimer's disease,Huntington's disease,Amyotrophic lateral sclerosisand multiple system atrophy (MSA).
    The initiation and progression of NDs is generally considered to be induced by oxidative stress arising from an imbalance of oxidants and antioxidants. One of the most important antioxidants against oxidative stress is glutathione (GSH),which is a tripeptide composed of cysteine,glutamate and glycine. Among these precursor amino acids,cysteine is the determinant of neuronal GSH synthesis. Cysteine uptake in the neurons is mostly mediated by excitatory amino acid carrier 1 (EAAC1),a member of the sodium-dependent excitatory amino acid transporters. Interestingly,it has been reported that one miRNA,miR-96-5p,regulates the neuroprotective effect of GSH by directly regulating EAAC1 expression. Furthermore,the expressions of miR-96-5p and its target EAAC1 are specifically deregulated in the brains of patients with MSA,suggesting that deregulated miR-96-5p induces MSA via EAAC1 down-regulation. Since miR-96-5p regulation of EAAC1 expression and GSH level is indicated to be under circadian control,a greater understanding of rhythmic miRNA regulation could lead to the use of miRNA in chronotherapy for ND.
    In this review,we focus on the role of miRNA in the mechanism of GSH synthesis and metabolism; particularly with respect to a critical transport system of its rate-limiting substrate via EAAC1,as well as on the implications and chronotherapeutic potential of miRNA for NDs.


    1.   Introduction

    The textural, sensorial and functional quality attributes of Cheddar cheese evolve during the aging of the cheese and reflect the combined influence of the dynamic microbiological, biochemical, and physico-chemical activities and reactions [1,2,3,4]. The main three biochemical cascades that occur during cheese aging are glycolysis, lipolysis and proteolysis [2,5,6]. Among these, proteolysis is considered the most important and most complex series of events [2,7,8]. The proteolytic cascade that occurs during cheese aging consists of enzymatic degradation of the casein constituents of the cheese matrix and the accumulation of a very heterogeneous population of peptides of different molecular weights and free amino acids [5,6,9,10]. A certain proportion of these free amino acids becomes involved in catabolic reactions the products of which have a major impact on the flavor and aroma characteristics of the cheese [5,10,11]. The type, rate, and extent of the proteolytic activities that occur during the aging of Cheddar cheese are governed by combined effects of the type and concentration of proteolytic agents that are included in the curd, curd composition, and the aging conditions [2,5,6]. The proteolytic agents in Cheddar cheese produced with pasteurized milk include the indigenous proteolytic enzymes of milk, plasmin and cathepsin D, heat-stable proteolytic enzymes of somatic cells and psychrotrophic bacteria, the proportion of milk coagulant that is retained in the curd, as well as the proteolytic enzymes of starter- and non-starter lactic acid bacteria [6,7,12,13,14,15,16,17,18]. The dynamics of the proteolytic activities during cheese aging are governed by the combined effects of curd composition, pH, salt-in-moisture (S/M), ionic strength and ionic composition [2,5,19,20]. Cheddar cheese is commonly aged isothermally at 6-8 ℃ [21] and the effect of aging temperature on proteolysis during cheese aging has been recognized and has been exploited as an effective means for accelerating cheese aging [6,21,22,23,24,25,26,27,28,29,30,31]. For example, Cheddar cheese that had been aged at different time-at-temperature programs at temperatures ranging from 7 to 20 ℃ exhibited significant time-at-temperature-dependent differences in microstructural, textural, and sensorial characteristics that reflected the effect of the aging conditions on the extent of proteolysis [21,26]. Aging Cheddar cheese at an elevated temperature allows enhancing its aging process, however, it can also lead to the evolution of microbiological, textural and sensorial defects [6,30,31]. It has been suggested that an accelerated aging temperature of 12 ℃ is optimal in order to limit adverse effects of high aging temperature on proteolysis and, consequently, texture and flavor [23,24,30]. The information about the effects of non-isothermal aging conditions on proteolysis is relatively limited and has been established for cheeses that had been subjected to temperatures higher than 10 ℃ [21,26]. Mitigating challenges that are associated with disrupt supply chain are likely to require modulating the rate of cheese aging without introducing a major acceleration effect that are known to lead to the evolution of textural and sensorial defects [24]. Introducing such capabilities requires developing information about the effects of relatively small changes in aging temperature on proteolysis. Additionally, it has to be recognized that, unfortunately, maintaining isotropic temperature distribution in cheese aging rooms is a common challenge and cheeses that are stored at different domains in a given aging room experience different time-at-temperature conditions. Recently, it has been demonstrated that both an electronic nose and consumers could detect sensorial differences between Cheddar cheeses that had been aged at 10 ℃ and 7 ℃ [27]. Data about the extent to which small variations in aging temperature affect proteolysis during aging of Cheddar cheese has been established only to a very limited extent. The objective of our research was to age FF and RF Cheddar cheeses at different time-at-temperature aging regimes ranging from 5 to 8 ℃ and to investigate the effects of these conditions on proteolysis during 6 months of aging.

    2.   Materials and methods

    2.1.   Cheeses

    Ten-day old full-fat (FF) and reduced-fat (RF) Cheddar cheeses were delivered, at 4-6 ℃, to our laboratory. Both cheeses were manufactured on the same day from the same batch of pooled milk, using the same coagulant and starter cultures, at a California creamery. Immediately upon arrival, the cheeses were cut into 1 kg portions that were then vacuumed packaged in BK1 Cryovac plastic bags (W.R. Grace Co., Duncan, SC). The packaged cheeses were aged for 180 days at different isothermal and non-isothermal time-at-temperature programs (Table 1). Cheeses were denoted according to their type (FF or RF) and the time-at-temperature program at which they were aged. For example, FF5 and RF8 were full-fat and reduced-fat Cheddar cheeses that were aged for 180 at 5 and 8 ℃, respectively. Similarly, FF585AC was a full-fat Cheddar cheese that was aged for 30 days at 5 ℃ than for 60 days at 8 ℃, and for additional 90 days at 5 ℃.

    Table 1.  Time-at-temperature details of the aging programs.
    Program Time-at-temp details
    5 Isothermal aging at 5 ℃ for 180 days
    5-8 A 30 days at 5 ℃ and then 150 days at 8 ℃
    5-8 B 60 days at 5 ℃ and then 120 days at 8 ℃
    5-8-5 AB 30 days at 5 ℃, 30 days at 8 ℃, and then 120 days at 5 ℃
    5-8-5 AC 30 days at 5 ℃, 60 days at 8 ℃, and then 90 days at 5 ℃
    8 Isothermal aging at 8 ℃ for 180 days
    8-5 A 30 days at 8 ℃ and then 150 days at 5 ℃
    8-5 B 60 days at 8 ℃ and then 120 days at 5 ℃
    8-5-8 AB 30 days at 8 ℃, 30 days at 5 ℃, and then 120 days at 8 ℃
    8-5-8 AC 30 days at 8 ℃, 60 days at 5 ℃, and then 90 days at 8 ℃
     | Show Table
    DownLoad: CSV

    2.2.   Analyses

    2.2.1.   Cheese composition

    The moisture, protein, fat, ash and salt contents of the FF and RF cheeses were determined at a cheese age of 10 days according to the Standard Methods of analyzing milk and dairy products [32]. Moisture content was determined gravimetrically, after vacuum drying for 12 h [32]. Protein content was determined according to the macro-Kjeldahl method, using a nitrogen-to-protein conversion factor of 6.38 [32]. Fat content was determined according to the Rose-Gotlieb method and ash content was determined gravimetrically after incineration in a muffle furnace at 550 ℃ [32]. Salt content of the cheeses was determined according to the Volhard method [32]. The results of the latter analysis and those of the afore-mentioned moisture content analysis were used to calculate the concentration (%) of salt in the aqueous phase of the cheese, that is salt-in-moisture (S/M). The pH of the investigated cheeses was determined using an Orion Star pH meter equipped with a spear-tip glass electrode (Thermo- Fisher Scientific). In all cases, duplicate samples were analyzed in triplicate (N X n = 6).

    2.2.2.   Cheese fractionation

    The effects of the investigated aging programs on proteolysis during cheese aging were investigated by monitoring the accumulation of three cheese-N fractions that has been indicated as cheese aging indices [7,33]. These consisted of the cheese-N fraction that was soluble at pH 4.6 (pH 4.6SN), the Cheese-N fraction that was soluble in 12% tri-chloroacetic acid (12TCASN) and that Cheese-N fraction that was soluble in 5% Phospho-tungstic acid (5PTASN) [7,33,34,35,36]. The investigated cheese fractions were prepared as previously described, with some modifications [9,33,34,35]. Briefly, grated cheese (200 g) was mixed with 400 mL of de-ionized water (Millipore, 18.2 MW.cm) and the mixture was homogenized for 3 min using a model 34BL97 Warning Blender (Dynamic Corp., New Hartford, CT) operated at maximum speed. The homogenate was stirred for 30 min at 25 ℃ and was then centrifuged for 20 min at 3000 X g. The supernatant was filter through a layer of glass wool (Fisher Scientific, Fair Lawn, NJ) and the pH of the filtrate was adjusted to pH 4.6 using 1.4N HCl. The mixture was centrifuged for 20 min at 3000 X g and, the supernatant was filtered through a Number 1 Whatman filter paper (Fisher Scientific, Fair Lawn, NJ). The filtrate was denoted as pH 4.6-soluble N (pH 4.6SN). A portion (45 mL) of the pH4.6SN fraction was mixed with 15 mL of 48% (w/v) TCA (Sigma Chemical Co., St. Luis, MO). The mixture was incubated at 25 ℃ for 12 h and was then centrifuged for 20 min at 3000 X g. The supernatant was filtered through No1 Whatman filter paper and the filtrate was denoted 12%TCA-soluble N (12TACSN). The cheese N fraction that was soluble in 5% PTA was preparing by mixing 50 mL of the 4.6SN fraction with 3.95 mL of H2SO4 and 15 mL of 33.3% (w/w) PTA (Sigma Chemical Co. St. Luis, MO). After incubation for 12 h at 25 ℃, the mixture was centrifuged at 3000 X g for 20 min, the supernatant was filtered through a No1 Whatman filter paper and the filtrate was denoted as 5% PTA-soluble N fraction (5PTASN). In all cases, the N content of the afore-mentioned fractions was determined by the macro-Kjeldhal analysis and the results were expressed as percent of total cheese N. In all cases, duplicate samples were analyzed in triplicates (N x n = 6).

    2.2.3.   Statistical analysis

    The significance of the resulted was challenged, at p < 0.05, by ANOVA using the SigmaStat software (Jandel Scientific Software, San Rafael, CA, USA). Line equations were established using the trendline tools included in Microsoft Excel software package (Microsoft Office Professional Plus 2016 (Microsoft, Redmond, WA, USA).

    3.   Results and discussion

    3.1.   Cheese composition

    The composition of the 10d old cheeses is detailed in Table 1. The fat and protein content of the RF cheese was about 33% lower and 28% higher than that of the FF Cheddar, respectively (Table 1). The pH of the two cheeses did not differ significantly (p > 0.05) and the S/M content of the RF cheese was significantly higher (p < 0.05) than that in the FF cheese. In the case of Cheddar cheese, the S/M is adjusted to be at least 4.5%. A lower S/M can promote an excessive extent of proteolysis that, in many cases can lead to the accumulation of bitter peptide originating mainly from β-CN [37]. Reduced- and low-fat Cheddar cheeses have been reported to be prone to the evolution of higher-than desired lactic acid content during cheese making [38]. The similar pH of the cheeses at 10 days of age suggested that the RF cheese had been produced at conditions that prevented the excessive evolution of the pH. Alternatively, the similar pH can be explained in light of the higher protein content of the RF cheese that presented a higher buffering capacity than that in the FF cheese [9,38].

    At a cheese age of 10 d, prior to being subjected to the different time-at-temperature aging conditions, the proportion of pH 4.6SN in the FF cheese was 14.6% higher than that in the RF cheese (Table 2). The proportions of the 12TCASN and of the 5PTASN in the 10d old FF Cheddar was 21.3 and 23.1% higher than that in the 10d old RF cheese, respectively (Table 2). Results thus indicated that overall, at the age of 10 days, the FF Cheddar exhibited a higher extent of proteolysis than that RF cheese. Because both cheeses were manufactured from the same batch of milk, this result can be probably attributed to the lower S/M of the FF cheese that allowed a higher extent of mainly primary proteolysis during the first 10 days following cheese making [9,39].

    Table 2.  Composition of the 10d old FF and RF Cheddar cheeses.
    Constituent FF Cheddar RF Cheddar
    Moisture (%) 39.12 ± 0.41 43.93 ± 0.39
    Fat (%) 32.80 ± 0.46 21.66 ± 0.25
    Protein (%) 22.50 ± 0.23 28.83 ± 0.56
    Ash (%) 4.21 ± 0.11 3.99 ± 0.02
    Salt (%) 1.46 ± 0.02 1.98 ± 0.03
    S/M (%) 3.70 ± 0.04 4.50 ± 0.04
    pH 5.16 ± 0.05 5.10 ± 0.05
    pH4.6 SN (% TN) 6.35 ± 0.31 5.54 ± 0.21
    12TCASN (% TN) 3.36 ± 0.31 2.77 ± 0.21
    5PTA (% TN) 1.12 ± 0.05 0.91 ± 0.05
     | Show Table
    DownLoad: CSV

    3.2.   Effects of aging conditions on proteolysis

    3.2.1.   General

    The results (Tables 3-9) have to be assessed in light of the different proteolytic activities that occur at different stages of the aging process. In general, at any given time, the level of each of the investigated cheese fractions represented the overall balance between proteolytic events that continuously hydrolyzed the cheese caseins, throughout the 180 aging days, and the involvement of free amino acids from the pool of the accumulated proteolytic products, in catabolic reactions [10,36]. Changes, with aging time, in the level of the accumulation of the investigated fractions represented the manifestation of different enzymatic and microbiological activities at different stages of the aging process as well as the effects of cheese composition and aging conditions on these events [2,5]. At early stages of the aging, proteolysis is mainly governed by the activity of the residuals of the coagulant that have been retained in the curd, plasmin, heat-stable proteases that are associated with somatic cells and psychrotrophic bacteria, and the extracellular, cell envelope-associated proteinase of Lactococccus [2,7]. At later stages, after the starter and non-starter lactic acid bacteria undergo autolysis, proteolytic products that have accumulated inside the bacterial cells as well as the microbial proteases and peptidases are released into the curd [7,11,40]. The activity of the latter becomes a significant contributor to the proteolytic cascade that result in the continuous accumulation of a very heterogeneous population of peptides and free amino acids, pending the consumption of the cheese [5,7,8,10,11].

    Table 3.  Line equations describing the accumulation of the investigated cheese-N fractions during isothermal aging of FF and RF cheeses at 5 ℃ and 8 ℃.
    Cheese/fraction Line equation R2
    FF8/pH4.6SN Y=3E − 06X3 − 0.0012X2 + 0.2165X + 4.7492 0.9878
    FF5/pH4.6SN Y=3E − 06x3 − 0.0013x2 + 0.1957x + 4.7001 0.9938
    RF8/ pH4.6SN Y=4E − 06X3 − 0.0016X2 + 0.2778X + 3.4744 0.9867
    RF5/ pH4.6SN Y=1E − 06X3 + 3E − 05X2 + 0.1155X + 4.4373 0.9895
    FF8/12TCASN Y=−9E − 0.5X2 + 0.077X + 3.0278 0.9837
    FF5/12TCASN Y=−7E − 05X2 + 0.0461X + 3.4024 0.9610
    RF8/ 12TCASN Y=−0.0002X2 + 0.0994X + 1.9454 0.9945
    RF5/ 12TCASN Y=−6E − 05X2 + 0.0539X + 2.2018 0.9933
    FF8/5PTASN Y=5E − 05X2 + 0.0144 + 1.1231 0.9907
    FF5/5PTASN Y=−5E − 05X2 + 0.0236X + 0.9558 0.9961
    RF8/ 5PTASN Y=−E5 − 05X2 + 0.0305X + 0.6071 0.9983
    RF5/ 5PTASN Y=1E − 05X2 + 0.0089X + 0.8204 0.9928
     | Show Table
    DownLoad: CSV
    Table 4.  Changes in the proportion of pH 4.6-SN (% of TN) during aging of FF Cheddar cheese at different aging programs.
    Program pH4.6SN (% of TN)
    30 days 60 days 90 days 120 days 180 days
    5 9.82b 12.54b 13.76d 15.56e 17.07e
    5-8A 9.82b 13.77a 15.98b 17.23c 20.31c
    5-8B 9.82b 12.54b 13.92d 15.65e 19.91c
    5-8-5AB 9.82b 13.77a 15.98b 15.60e 18.63d
    5-8-5AC 9.82b 13.77a 15.98b 16.98c 20.06c
    8 11.15a 13.94a 16.05b 19.43a 22.41a
    8-5A 11.15a 12.35b 14.84c 17.34c 20.42c
    8-5B 11.15a 13.94a 16.70a 18.44b 21.37b
    8-5-8AB 11.15a 12.35b 15.71b 16.92c 20.05c
    8-5-8C 11.15a 12.35b 14.84c 16.56d 20.12c
    abcdeFor a given column, means that are followed by different letters differ significantly (p < 0.05).
     | Show Table
    DownLoad: CSV
    Table 5.  Changes in the proportion of pH 4.6-SN during aging of RF Cheddar cheese at different aging programs.
    Program pH 4.6SN (% of TN)
    30 d 60 d 90 d 120 d 180 d
    5 8.16b 10.51c 14.92d 16.10e 18.55f
    5-8 A 8.16b 13.78a 16.57b 18.88b 23.47a
    5-8 B 8.16b 10.51c 14.31d 19.50b 22.71b
    5-8-5 AB 8.16b 13.78a 15.49c 16.90d 18.31f
    5-8-5 AC 8.16b 13.78a 16.57b 19.20b 20.37e
    8 11.71a 14.17a 18.10a 20.47a 23.86a
    8-5 A 11.71a 13.92a 14.52d 15.70e 18.78ef
    8-5 B 11.71a 14.17a 15.85c 17.33c 19.14e
    8-5-8 AB 11.71a 13.90a 15.70c 18.89b 22.23c
    8-5-8 AC 11.71a 13.92a 14.52d 17.76c 21.32d
    abcdefFor a given column, means that are followed by different letters differ significantly (p < 0.05).
     | Show Table
    DownLoad: CSV
    Table 6.  Changes in the proportion of 12% TCA-SN during aging of FF Cheddar cheese at different aging programs.
    Program 12TCASN (% of TN)
    30 days 60 days 90 days 120 days 180 days
    5 5.33b 6.20c 6.61e 7.79f 9.53g
    5-8 A 5.33b 6.89b 8.98c 10.76a 13.40b
    5-8 B 5.33b 6.20c 8.23d 9.21e 13.26b
    5-8-5 AB 5.33b 6.89b 8.85c 9.52d 10.07f
    5-8-5 AC 5.33b 6.89b 8.98c 9.78c 10.52e
    8 5.84a 7.18a 9.69a 10.35b 14.15a
    8-5 A 5.85a 6.73c 8.42d 9.32e 10.72f
    8-5 B 5.85a 7.18a 8.50d 9.23e 10.93d
    8-5-8 AB 5.85a 6.73b 9.36b 10.49b 13.46b
    8-5-8 AC 5.85a 6.73b 8.42d 9.42d 11.54c
    abcdefgFor a given column, means that are followed by different letters differ significantly (p < 0.05).
     | Show Table
    DownLoad: CSV
    Table 7.  Changes in the proportion of 12% TCA-SN during aging of RF Cheddar cheese at different aging programs.
    Program 12TCASN (% of TN)
    30 d 60 d 90 d 120 d 180 d
    5 3.70a 5.11d 6.94c 7.52c 9.00f
    5-8 A 3.70a 6.50b 7.88b 9.15b 12.06b
    5-8 B 3.70a 5.11d 7.88b 9.42b 11.70c
    5-8-5 AB 3.70a 6.50b 7.25c 8.41b 9.70e
    5-8-5 AC 3.70a 6.50b 7.88b 9.30b 10.46d
    8 4.99b 6.90a 9.53a 10.47a 12.95a
    8-5 A 4.99b 6.27c 7.34c 8.24b 10.36d
    8-5 B 4.99b 6.90a 7.45b 9.53b 9.22f
    8-5-8 AB 4.99b 6.27c 7.83b 10.05a 11.41d
    8-5-8 AC 4.99b 6.27c 7.34c 8.73b 10.40d
    abcdefFor a given column, means that are followed by different letters differ significantly (p < 0.05).
     | Show Table
    DownLoad: CSV
    Table 8.  Changes in the proportion of 5% PTA-SN (% of TN) during aging of FF Cheddar cheese at different aging programs.
    Program 5PTASN (% of TN)
    30 d 60 d 90 d 120 d 180 d
    5 1.71a 2.22a 2.63c 3.09c 3.65d
    5-8 A 1.71a 2.05a 2.91ab 3.55a 4.84b
    5-8 B 1.71a 2.22a 2.43d 2.50e 4.72b
    5-8-5 AB 1.71a 2.05a 3.01a 3.45a 4.20c
    5-8-5 AC 1.71a 2.05a 2.91ab 3.22b 3.84d
    8 1.77a 2.20a 2.86ab 3.33b 5.28a
    8-5 A 1.77a 1.97a 2.68c 3.02c 3.47d
    8-5 B 1.77a 2.20a 2.50d 3.32b 3.81d
    8-5-8 AB 1.77a 1.97a 3.11a 3.33b 4.75b
    8-5-8 AC 1.77a 1.97a 2.68c 2.76d 3.83d
    abcdFor a given column, means that are followed by different letters differ significantly (p < 0.05).
     | Show Table
    DownLoad: CSV
    Table 9.  Changes in the proportion of 5% PTA-SN during aging of RF Cheddar cheese at different aging programs.
    Program 5PTASN (% of TN)
    30 days 60 days 90 days 120 days 180 days
    5 1.12b 1.38d 1.62d 2.13d 2.74c
    5-8 A 1.12b 1.87b 2.35b 2.96c 4.23b
    5-8 B 1.12b 1.38d 2.23b 2.85c 3.83b
    5-8-5 AB 1.12b 1.87b 2.02c 2.16d 2.98c
    5-8-5 AC 1.12b 1.87b 2.35b 3.14b 3.59b
    8 1.43a 2.36a 2.90a 3.55a 4.52b
    8-5 A 1.43a 1.65c 1.85c 2.04d 3.44b
    8-5 B 1.43a 2.36a 2.90a 3.27b 3.93b
    8-5-8 AB 1.43a 1.65c 2.23b 3.65a 4.71a
    8-5-8 AC 1.43a 1.65c 1.85c 2.90c 3.62b
    abcdFor a given column, means that are followed by different letters differ significantly (p < 0.05).
     | Show Table
    DownLoad: CSV
    3.2.2.   Isothermal aging

    The two isothermal aging programs to which the cheeses were subjected differed by only 3 ℃ and both temperatures were below 10 ℃. At both isothermal aging programs, the proportion of the pH 4.6SN in both FF and RF cheeses increased with aging time and in all cases its level in the cheeses was proportionally related to the aging temperature (Tables 4 and 5). The changes in the pH 4.6SN with aging time could be best described (R2 = 0.9867-0.9938) by polynomial expressions (Table 3), similar to what has been earlier reported for FF and LF Cheddar cheese [33]. The observed changes in the level of the accumulated pH 4.6SN reflected the overall balance between the extent of primary proteolysis and secondary proteolytic reactions as well as the catabolism of free amino acids [7,11]. After 60, 120 and 180 days, the proportion of pH 4.6SN in the FF8 cheese was about 13.5, 24.9, and 31.3% higher than that in the FF5 cheese, respectively (Table 4). Similarly, in the RF cheeses (Table 5), after 60, 120 and 180 days, the proportion of pH 4.6SN in the cheeses that had been aged at 8 ℃ was 34.8, 27.1, and 28.6%, higher than that in the RF cheeses that had been aged at 5 ℃, respectively. For a given aging time, the differences between FF and RF cheeses in the level of the pH 4.6SN fraction ranged from 4.4 to 20% and from 1.7 to 14.6%, for cheeses aged at 5 ℃ and 8 ℃, respectively (Tables 4 and 5). Results thus indicated that the effect of aging temperature on the extent of proteolytic activities was greater than the effect of cheese composition.

    The changes with aging time in the proportion of the 12TCASN in the isothermally-aged FF and RF cheeses are depicted in Tables 6 and 7, respectively, and the polynomial line equations that best describe these changes (R2 = 0.961-0.9945) are presented in Table 3. The levels of 12TCASN that accumulated in the FF and RF cheeses during aging at 8 ℃ was 1.10-1.50 and 1.29-1.39 times higher than that in the cheeses that were aged at 5 ℃, respectively (Tables 6 and 7). During the first 60 days of aging at 5 ℃, the proportion of 12TCASN that accumulated in the FF cheese was 1.21-1.44 times higher than that accumulated in the RF cheese, however, at a longer aging time, the levels of the 12TCASN differed only slightly between the FF and the RF cheeses (Tables 6 and 7). The accumulation of the 5PTASN fraction was proportionally related to the aging time and the polynomial expressions that best describe (R2 = 0.9928-0.9983) the changes in this fraction with aging time are presented in Table 3. The accumulation of 5PTASN in the RF8 cheese was 1.28-1.79 times higher than that accumulated in the RF5 cheese (Table 9). Throughout the first 120 aging days, the level of 5PTASN in the FF8 cheese differed by less than 10% from that accumulated at FF5 cheese. However, after 180 days, the level of the 5PTASN in the FF8 cheese was 1.45 times higher than that in the FF5 cheese (Tables 8 and 9). The differences in the level of the 5PTASN that accumulated in the FF5 and FF8 cheese varied by 23-63% and by 6.2-16.6% from that in the RF5 and RF8 cheeses, respectively (Tables 8 and 9). The results of the isothermal aging indicated the significant effect that a 3 ℃ difference in aging temperature had on the accumulation of all the investigated cheese-N fractions. The results thus indicated that a 3 ℃ difference in aging temperature effectively and significantly enhanced the proteolytic cascade in both the FF and RF cheeses.

    3.2.3.   Non-isothermal aging

    Eight different non-isothermal time-at-temperature aging regimes were investigated for their effects on the proteolytic cascades that occur during aging of FF and RF Cheddar cheeses. The different aging regimes consisted of two "cold-to-warmer" and two "warm-to-colder" programs, two cold-to-warmer-back to colder" as well as two regimes of "warm-to-colder-back to warmer" regimes. The symmetric design of the aging programs was aimed at assessing the influence of a small change in aging temperature and the impact of the stage, during aging, at which such change is made. In all cases, although the temperature difference between the "warm" and "cold" phases of the aging was 3 ℃, the accumulation of the proteolytic products was affected (p < 0.05) by the combined influence of the aging time-at-temperature details and cheese composition (Tables 4-9). Results (Tables 4-9) indicated that increasing or decreasing the aging temperature by only 3 ℃ significantly affected the proteolytic cascade in the cheese in a way that enhanced or slowed down the accumulation of proteolytic products in the cheese, respectively (p < 0.05). Results of the study also indicated that the stage at which the aging temperature is changed had a significant (p < 0.05) influence on the accumulation of the different proteolytic products (Tables 4-9).

    Increasing the aging temperature from 5 to 8 ℃ enhanced the accumulation of the pH 4.6SN fraction in the cheese, thus indicating the effect of aging temperature on the proteolytic cascade. For example, 30d after increasing the aging temperature by 3 degrees, the pH 4.6SN that accumulated in the FF58A, FF58AB, and FF58AC cheeses was significantly higher (p < 0.05) than that in the FF5 cheese and similar (p > 0.05) to that in the FF8 and the FF85B cheeses (Table 4). Similarly, reducing the temperature from 8 to 5 ℃ slowed down the accumulation of the pH4.6SN, at an aging program-specific manner.

    After 180d, the level of pH 4.6SN that accumulated in the FF cheeses was in the order: FF8 > FF85B > FF85A = FF58A = FF58B = FF585AC = FF858AB = FF858AC > FF585AB > FF5. The accumulation of the pH 4.6SN in the non-isothermally aged RF cheeses was influenced by the time-at-temperature conditions during aging in a way similar to that exhibited by the FF cheeses (Tables 4 and 5). It was interesting to note (Tables 4 and 5) that after 6 aging months, the pH 4.6SN that accumulated in the RF58A cheese was similar to that in the RF8 cheese (p > 0.05) while that in the RF85A cheese was similar to the level that accumulated in the RF5 cheese (p > 0.05).

    After 180d, the level of the pH4.6SN that accumulated in the RF cheeses was in the order: RF8 = RF58A > RF58B > RF858AB > RF858AC > RF85B = RF85A = RF585AC > RF585AB = RF5 (Table 5). Increasing or lowering the aging temperature by 3 ℃ during aging provided an effective means for modulating the accumulation of the pH 4.6WSN in Cheddar cheese and, potentially its aging rate. For example, after 60, 90 and 120 days, the accumulation of pH 4.6SN in the FF58A cheese was similar to that in FF5 cheese after 90, 120, and 180 aging days, respectively (Table 4).

    The pH 4.6SN fraction of cheese consists of a very heterogeneous population of proteolytic products ranging from high-molecular weight peptides to free amino acids [7,8,33]. The composition of the pH 4.6SN fraction changes with aging time in a way that reflects the increasing activities of peptidases that degrade the products of the primary proteolysis, on one hand, and the manifestation of amino acids catabolism, on the other hand [2,7]. The degradation of the products of primary proteolysis by microbial proteases and peptidases has been shown to be reflected in the changes, with aging time, in the accumulation of 12TCASN and 5PTASN fractions [7,8].

    The 12TCASN fraction of cheese contains proteolytic products consisting of medium- and low-MW peptides and free amino acids [7,8]. Results (Tables 6 and 7) indicated that the accumulation of this fraction in the FF and RF Cheddar cheeses was significantly influenced by the aging programs in a time-at-temperature details-specific manner (p < 0.05). For example, 30, 60, 90, and 120d after its aging temperature was increased from 5 to 8 ℃, the level of the 12TCASN fraction in the FF58A was 1.11, 1.35, 1.38, and 1.41 times higher (p < 0.05) than that in FF5 cheese, respectively (Table 6). Similarly, 30, 60, 90, and 120d after its aging temperature was lowered from 8 to 5 ℃, the level of the 12TCASN fraction in the FF85A was 0.88, 0.86, 0.90, and 0.76 times of that accumulated in the FF8 cheese, respectively (Table 6). The accumulation of the 12TCASN in the RF cheeses was also significantly influenced (p < 0.05) by the aging conditions (Table 7). For example, 30, 60, 90, and 120d after its aging temperature was increased from 5 to 8 ℃, the level of the 12TCASN fraction in the RF58A was 1.14, 1.45, 1.22, and 1.34 times higher than that in the RF5 cheese, respectively (Table 7). Lowering the aging temperature from 8 to 5 ℃ slowed down the accumulation of the 12TCASN fraction in the RF cheese. For example, 30, 60, 90, and 120d after its aging temperature was lowered from 8 to 5 ℃, the level of the 12TCASN fraction in the RF85A was 0.90, 0.77, 0.78, and 0.80 of that in the RF8 cheese, respectively (Table 7). In all other cases, for both RF and FF cheeses, the accumulation of the 12TCASN was significantly affected by the combined influence of the stage at which the temperature was changed and by the overall time during which the cheese was aged at 5 and at 8 ℃ (Tables 6 and 7).

    After 180 aging days, the level of the 12TCASN in the RF cheese was in the order: RF8 > RF58A > RF58B > RF585AC = RF85A = RF858AB = RF858AC > RF85B = RF5 (Table 7). After 180 aging days, the level of the 12TCASN that accumulated in the FF cheeses was in the order: FF8 > FF858AB = FF58B = FF58A > FF858AC > FF85B > FF585AC > FF85A = FF585AB > FF5 (Table 6).

    The 5PTASN fraction contains very small peptides of MW up to 600 Da and free amino acids. This fraction represents the pool of free amino acids that can become involved in catabolic reactions that flavor- and aroma-impacting compounds and thus has been identified as indicative of flavor development in cheeses [34]. At a given aging time, the level of 5PTASN represents the balance between the accumulation of small proteolytic products and their disappearance in catabolic reactions [10,11]. For both FF and RF cheeses, the changes, with aging time, in the level of 5PTASN was significantly (p < 0.05) influenced by the time-at-temperature details of the aging program (Tables 8 and 9). In the case of FF cheeses, similar (p > 0.05) levels of 5PTASN accumulated during the first 60 days of aging at all the investigated programs. However, at later stages of the aging, the accumulation of this fraction was significantly influenced by the time-at-temperature conditions (Tables 8 and 9), thus suggesting the increasing contribution, with aging time, of peptidases as well as of proteolytic products that were released into the curd after the lysis of starter and non-starter bacteria in the curd. After 90 and 120d, the level of the 5PTASN in the FF58A, FF58B, FF585AB, and FF585AC was 10-14% and 5-14% higher than that in the FF5 cheese, respectively (Table 8). The accumulation of the 5PTAASN in the RF cheeses was significantly influenced (p < 0.05) by the aging conditions (Table 9). 30, 60, 90, and 120d after its aging temperature was increased from 5 to 8 ℃, the level of the 5PTASN fraction in the RF58A was 1.36, 1.45, 1.38, and 1.71 times higher than that in the FF5 cheese, respectively (Table 9). Lowering the aging temperature from 8 to 5 ℃ slowed down the accumulation of the 5PTASN fraction in the RF cheese. For example, 30, 60, 90, and 120d after its aging temperature was lowered from 8 to 5 ℃, the level of the 5PTASN fraction in the RF85A was 0.70, 0.64, 0.58, and 0.76 of that in the RF8 cheese, respectively (Table 9). It was interesting to note that the overall highest level of this fraction was found after 120 and 180d in the RF858AB cheese (Table 9). This finding may suggest the influence of sequential changes in temperature on microbial autolysis at early stages of the aging process along with the overall time at which the cheese was aged at 8 ℃. After 180 aging days, the level of the 5PTASN that has accumulated in the RF cheeses was in the order: RF858AB > RF858AC = RF85B = RF85A = RF585AC = RF58B = RF58A > RF585AB = RF5 (Table 9). Similarly, after 180 aging days, the level of 5PTASN in the FF cheeses was in the order: FF8 > FF58A = FF58B = FF858AB > FF585AB > FF85B = FF858AC = FF585AC = FF5 (Table 8).

    The observed significant effects of time-at-temperature conditions on the accumulation of the 5PTASN were in agreement with the reported influence of small changes in aging temperature on the accumulation of L-glutamic acid in Cheddar cheese [36]. A correlation between flavor development and the accumulation of 5PTASN fraction during aging of Cheddar cheese has been established [7,31,33]. In light of the latter, the results of the present study clearly suggested that small changes in aging temperature within the range of 5 and 8℃ can potentially affect the development of flavor in both FF and RF Cheddar cheese.

    Results of the study have revealed differences between the extent to which the aging conditions affected the accumulation of the different cheese-N fractions in the FF and in the RF cheeses (Tables 4-9). The magnitude of such differences and their trend varied with aging time and were influenced by the aging conditions. After 60, 120, and 180 days of non-isothermal aging, the ratio of the pH 4.6SN fraction in the FF to that in the RF cheeses exhibited a mixed trend and was 0.89-1.19, 0.80-1.10, and 0.87-1.12, respectively (Tables 4 and 5). In most cases, the differences between the accumulation of the pH 4.6SN fraction in FF and RF cheeses were less than 20% and suggested the combined influence of the cheese composition and the time-at-temperature details of the aging on the accumulation of the pH 4.6SN fraction [9,41]. In all but 2 cases, the level of the 12TCASN fraction in the FF cheese was higher than that in the RF cheese (Tables 6 and 7). Throughout 180 days of isothermal aging, the ratio of the 12TCASN fraction in the FF cheese to that in the RF cheese was 0.95-1.44 and 0.99-1.117, for cheeses aged at 5 and 8 ℃, respectively. Results obtained during the non-isothermal aging indicated that the differences between the level of 12TCASN fraction that accumulated in the FF and the RF cheeses varied with the time-at-temperature details of the aging program. After 60, 120, and 180 days, the ratio of the 12TCASN fraction in the FF cheeses to that in the RF cheeses was, 1.06-1.21, 0.98-1.18, and 1.04-1.19, respectively. Results (Tables 8 and 9) indicated that throughout 180 days of isothermal aging, the ratio of the 5PTASN fraction in the FF cheese to that in the RF cheese was 1.33-1.62 and 0.93-1.23, for cheeses aged at 5 and 8 ℃, respectively. Results obtained during the non-isothermal aging indicated that in most cases the accumulation of the 5PTASN in the FF cheeses was to a higher level than that in the RF cheeses (Tables 8 and 9) and the differences between the level of 5PTASN fraction that accumulated in the FF and the RF cheeses varied with the time-at-temperature details of the aging program. After 60, 120, and 180 days, the ratio of the 5PTASN fraction in the FF cheeses to that in the RF cheeses was, 1.10-1.61, 0.88-1.60, and 0.97-1.41, respectively. Overall, the results of the study indicated that in most cases, the extent of proteolysis in the FF cheeses was higher than that in the RF, however, these differences were greatly affected by the time-at-temperature details of the aging program. The higher extent of proteolysis that was exhibited, in most cases, by the FF cheeses was similar to what has been previously reported and could be attributed to the effects of the lower protein-to-fat ratio in these cheeses [9,38,39,41]. It has been established that the latter had a major effect on the extent of proteolysis that could be attributed to the effects of lowering the fat content on the moisture-in-fat-free mass. This compositional change has been shown to affect the rate and extent of proteolysis during aging due to the impact on the evolution of pH during cheesemaking and aging, the retention of coagulant in the curd and the S/M in the cheese [9,38,39]

    Overall, results of the study have demonstrated that the proteolytic cascade that plays a major role in the aging of Cheddar cheese is significantly affected by the details of time-at-temperature during aging, even when the temperature changes by only 3 ℃. The results of the non-isothermal aging experiments have clearly demonstrated the potential for controlling not only the overall acceleration or deceleration of the proteolytic activities but also the time, during aging, at which the rate of the proteolytic cascade is modified. The significant among-aging-programs-differences in the accumulation of all the investigated cheese-N fraction represent opportunities for modulating the cheese ripening process, as needed. However, these same results also highlight the risks that are associated with aging cheese at conditions that allow the aging temperature to fluctuate, even slightly, during the aging and along the supply chain. The results thus highlight the need to tightly control the cheese aging temperature and suggest that falling short of meeting this goal is likely to lead to significant variations in the evolution of cheese quality attributes. Results (Tables 4-9) indicated that both primary proteolysis, that results in the accumulation of high- and medium-molecular-weight peptides, and the activity of microbial peptidases, that govern the accumulation of very small peptides and free amino acids, can be effectively modulated by small changes in aging temperature. The significant effect that temperature had on the accumulation of the different cheese-N fractions could be attributed to the effects of temperature on the rate of enzymatic reactions as well as on microbial autolysis and, probably, on the propagation of non-starter lactic acid bacteria during early stages of the aging process [4,6,30,42]. The ability to "tune" the progression of the proteolytic cascade has been suggested as an effective and inexpensive means for modulating the evolution of cheese quality attributes. Unlike most of the previous reports [6,30,31], the results of the present study clearly indicated that such opportunities can be exploited while maintaining the temperature lower than 10 ℃.

    4.   Conclusions

    The results of the study indicated that very small (3 ℃) changes in aging temperature had significant effects on the proteolytic cascade during aging of Cheddar cheese. The demonstrated capabilities to significantly modulate the evolution of proteolytic activities during aging at a temperature lower than 10 ℃ may open new potential opportunities for modulating the development of cheese quality attributes, such as texture and flavor, at conditions that are less likely to lead to the development of defects that are associated with aging at a temperature higher than 10 ℃. The results of the study offer a potential new approach for mitigating challenges that are associated with fluctuating market supply and demand as well as difficulties during disrupt supply chain. In light of the demonstrated significant effect of very small change in aging temperature on proteolysis during cheese aging, the results of the study highlight the critical importance of establishing and maintaining isotropic temperature distribution in cheese aging rooms. It has to be noted that although the significant effects of the investigated aging programs on the proteolytic cascade have been demonstrated, the impacts of these effects on the textural and sensorial characteristics of the cheese have yet to be investigated.

    Conflict of interest

    No conflict of interest has been reported by the authors

    Acknowledgments

    The authors express their gratitude to the California Dairy Research Foundation for providing a research fund to support this research.

    [1] Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854.
    [2] Lagos-Quintana M, Rauhut R, Lendeckel W, et al. (2001) Identification of novel genes coding for small expressed RNAs. Science 294: 853-858. doi: 10.1126/science.1064921
    [3] Lau NC, Lim LP, Weinstein EG, et al. (2001) An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294: 858-862. doi: 10.1126/science.1065062
    [4] Lee RC, Ambros V (2001) An extensive class of small RNAs in Caenorhabditis elegans. Science 294: 862-864. doi: 10.1126/science.1065329
    [5] Pasquinelli AE, Reinhart BJ, Slack F, et al. (2000) Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408: 86-89. doi: 10.1038/35040556
    [6] Ardekani AM, Naeini MM (2010) The Role of MicroRNAs in Human Diseases. Avicenna J Med Biotechnol 2: 161-179.
    [7] Reuter S, Gupta SC, Chaturvedi MM, et al. (2010) Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49: 1603-1616. doi: 10.1016/j.freeradbiomed.2010.09.006
    [8] Magenta A, Greco S, Gaetano C, et al. (2013) Oxidative stress and microRNAs in vascular diseases. Int J Mol Sci 14: 17319-17346. doi: 10.3390/ijms140917319
    [9] Rahal A, Kumar A, Singh V, et al. (2014) Oxidative stress, prooxidants, and antioxidants: the interplay. Biomed Res Int 2014: 761264.
    [10] Dringen R (2000) Metabolism and functions of glutathione in brain. Prog Neurobiol 62: 649-671. doi: 10.1016/S0301-0082(99)00060-X
    [11] Jomova K, Vondrakova D, Lawson M, et al. (2010) Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345: 91-104. doi: 10.1007/s11010-010-0563-x
    [12] Meister A (1988) On the discovery of glutathione. Trends Biochem Sci 13: 185-188. doi: 10.1016/0968-0004(88)90148-X
    [13] Maruyama Y, Yasuda R, Kuroda M, et al. (2012) Kokumi substances, enhancers of basic tastes, induce responses in calcium-sensing receptor expressing taste cells. PLoS One 7: e34489. doi: 10.1371/journal.pone.0034489
    [14] Ueda Y, Yonemitsu M, Tsubuku T, et al. (1997) Flavor characteristics of glutathione in raw and cooked foodstuffs. Biosci Biotechnol Biochem 61: 1977-1980. doi: 10.1271/bbb.61.1977
    [15] Aoyama K, Watabe M, Nakaki T (2012) Modulation of neuronal glutathione synthesis by EAAC1 and its interacting protein GTRAP3-18. Amino Acids 42: 163-169. doi: 10.1007/s00726-011-0861-y
    [16] Kinoshita C, Aoyama K, Matsumura N, et al. (2014) Rhythmic oscillations of the microRNA miR-96-5p play a neuroprotective role by indirectly regulating glutathione levels. Nat Commun 5: 3823.
    [17] Ubhi K, Rockenstein E, Kragh C, et al. (2014) Widespread microRNA dysregulation in multiple system atrophy - disease-related alteration in miR-96. Eur J Neurosci 39: 1026-1041. doi: 10.1111/ejn.12444
    [18] Ha M, Kim VN (2014) Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15: 509-524. doi: 10.1038/nrm3838
    [19] Sevignani C, Calin GA, Siracusa LD, et al. (2006) Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome 17: 189-202. doi: 10.1007/s00335-005-0066-3
    [20] Cipolla GA (2014) A non-canonical landscape of the microRNA system. Front Genet 5: 337.
    [21] Lytle JR, Yario TA, Steitz JA (2007) Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc Natl Acad Sci U S A 104: 9667-9672. doi: 10.1073/pnas.0703820104
    [22] Henchcliffe C, Beal MF (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4: 600-609.
    [23] Finkel T, Holbrook NJ (2000) Oxidants, oxidative stress and the biology of ageing. Nature 408: 239-247. doi: 10.1038/35041687
    [24] Ray PD, Huang BW, Tsuji Y (2012) Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 24: 981-990. doi: 10.1016/j.cellsig.2012.01.008
    [25] Lee S, Choi E, Cha MJ, et al. (2014) Looking into a Conceptual Framework of ROS-miRNA-Atrial Fibrillation. Int J Mol Sci 15: 21754-21776. doi: 10.3390/ijms151221754
    [26] Magenta A, Cencioni C, Fasanaro P, et al. (2011) miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ 18: 1628-1639. doi: 10.1038/cdd.2011.42
    [27] Brabletz S, Brabletz T (2010) The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer? EMBO Rep 11: 670-677. doi: 10.1038/embor.2010.117
    [28] Mateescu B, Batista L, Cardon M, et al. (2011) miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med 17: 1627-1635. doi: 10.1038/nm.2512
    [29] Rosati J, Spallotta F, Nanni S, et al. (2011) Smad-interacting protein-1 and microRNA 200 family define a nitric oxide-dependent molecular circuitry involved in embryonic stem cell mesendoderm differentiation. Arterioscler Thromb Vasc Biol 31: 898-907. doi: 10.1161/ATVBAHA.110.214478
    [30] Lin Y, Liu X, Cheng Y, et al. (2009) Involvement of MicroRNAs in hydrogen peroxide-mediated gene regulation and cellular injury response in vascular smooth muscle cells. J Biol Chem 284: 7903-7913. doi: 10.1074/jbc.M806920200
    [31] Lin H, Qian J, Castillo AC, et al. (2011) Effect of miR-23 on oxidant-induced injury in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 52: 6308-6314. doi: 10.1167/iovs.10-6632
    [32] Papaioannou MD, Lagarrigue M, Vejnar CE, et al. (2011) Loss of Dicer in Sertoli cells has a major impact on the testicular proteome of mice. Mol Cell Proteomics 10: M900587MCP900200.
    [33] Wang Q, Wang Y, Minto AW, et al. (2008) MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 22: 4126-4135. doi: 10.1096/fj.08-112326
    [34] Xu Y, Fang F, Zhang J, et al. (2010) miR-17* suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymes. PLoS One 5: e14356. doi: 10.1371/journal.pone.0014356
    [35] Zhang X, Ng WL, Wang P, et al. (2012) MicroRNA-21 modulates the levels of reactive oxygen species by targeting SOD3 and TNFalpha. Cancer Res 72: 4707-4713. doi: 10.1158/0008-5472.CAN-12-0639
    [36] Fleissner F, Jazbutyte V, Fiedler J, et al. (2010) Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. Circ Res 107: 138-143. doi: 10.1161/CIRCRESAHA.110.216770
    [37] Zhao H, Tao Z, Wang R, et al. (2014) MicroRNA-23a-3p attenuates oxidative stress injury in a mouse model of focal cerebral ischemia-reperfusion. Brain Res 1592: 65-72. doi: 10.1016/j.brainres.2014.09.055
    [38] Xia XG, Zhou H, Samper E, et al. (2006) Pol II-expressed shRNA knocks down Sod2 gene expression and causes phenotypes of the gene knockout in mice. PLoS Genet 2: e10. doi: 10.1371/journal.pgen.0020010
    [39] Bai XY, Ma Y, Ding R, et al. (2011) miR-335 and miR-34a Promote renal senescence by suppressing mitochondrial antioxidative enzymes. J Am Soc Nephrol 22: 1252-1261. doi: 10.1681/ASN.2010040367
    [40] Togliatto G, Trombetta A, Dentelli P, et al. (2014) Unacylated ghrelin (UnAG) induces oxidative stress resistance in a glucose intolerance mouse model and peripheral artery disease by restoring endothelial cell miR-126 expression. Diabetes 64: 1370-82.
    [41] Ji G, Lv K, Chen H, et al. (2013) MiR-146a regulates SOD2 expression in H2O2 stimulated PC12 cells. PLoS One 8: e69351. doi: 10.1371/journal.pone.0069351
    [42] Meng X, Wu J, Pan C, et al. (2013) Genetic and epigenetic down-regulation of microRNA-212 promotes colorectal tumor metastasis via dysregulation of MnSOD. Gastroenterology 145: 426-436 e421-426. doi: 10.1053/j.gastro.2013.04.004
    [43] Liu X, Yu J, Jiang L, et al. (2009) MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genom Proteom 6: 131-139.
    [44] Kriegel AJ, Fang Y, Liu Y, et al. (2010) MicroRNA-target pairs in human renal epithelial cells treated with transforming growth factor beta 1: a novel role of miR-382. Nucleic Acids Res 38: 8338-8347. doi: 10.1093/nar/gkq718
    [45] Tu H, Sun H, Lin Y, et al. (2014) Oxidative stress upregulates PDCD4 expression in patients with gastric cancer via miR-21. Curr Pharm Des 20: 1917-1923. doi: 10.2174/13816128113199990547
    [46] Haque R, Chun E, Howell JC, et al. (2012) MicroRNA-30b-mediated regulation of catalase expression in human ARPE-19 cells. PLoS One 7: e42542. doi: 10.1371/journal.pone.0042542
    [47] Wang Q, Chen W, Bai L, et al. (2014) Receptor-interacting protein 1 increases chemoresistance by maintaining inhibitor of apoptosis protein levels and reducing reactive oxygen species through a microRNA-146a-mediated catalase pathway. J Biol Chem 289: 5654-5663. doi: 10.1074/jbc.M113.526152
    [48] Xu X, Wells A, Padilla MT, et al. (2014) A signaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance. Carcinogenesis 35: 2457-2466. doi: 10.1093/carcin/bgu159
    [49] Espinosa-Diez C, Fierro-Fernandez M, Sanchez-Gomez FJ, et al. (2014) Targeting of gamma-glutamyl-cysteine ligase by miR-433 reduces glutathione biosynthesis and promotes TGF-beta-dependent fibrogenesis. Antioxid Redox Signal.
    [50] Dong X, Liu H, Chen F, et al. (2014) MiR-214 promotes the alcohol-induced oxidative stress via down-regulation of glutathione reductase and cytochrome P450 oxidoreductase in liver cells. Alcohol Clin Exp Res 38: 68-77. doi: 10.1111/acer.12209
    [51] Wang L, Huang H, Fan Y, et al. (2014) Effects of downregulation of microRNA-181a on H2O2-induced H9c2 cell apoptosis via the mitochondrial apoptotic pathway. Oxid Med Cell Longev 2014: 960362.
    [52] Maciel-Dominguez A, Swan D, Ford D, et al. (2013) Selenium alters miRNA profile in an intestinal cell line: evidence that miR-185 regulates expression of GPX2 and SEPSH2. Mol Nutr Food Res 57: 2195-2205. doi: 10.1002/mnfr.201300168
    [53] Jee MK, Jung JS, Choi JI, et al. (2012) MicroRNA 486 is a potentially novel target for the treatment of spinal cord injury. Brain 135: 1237-1252. doi: 10.1093/brain/aws047
    [54] Mutallip M, Nohata N, Hanazawa T, et al. (2011) Glutathione S-transferase P1 (GSTP1) suppresses cell apoptosis and its regulation by miR-133alpha in head and neck squamous cell carcinoma (HNSCC). Int J Mol Med 27: 345-352.
    [55] Moriya Y, Nohata N, Kinoshita T, et al. (2012) Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J Hum Genet 57: 38-45. doi: 10.1038/jhg.2011.126
    [56] Uchida Y, Chiyomaru T, Enokida H, et al. (2013) MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urol Oncol 31: 115-123. doi: 10.1016/j.urolonc.2010.09.017
    [57] Patron JP, Fendler A, Bild M, et al. (2012) MiR-133b targets antiapoptotic genes and enhances death receptor-induced apoptosis. PLoS One 7: e35345. doi: 10.1371/journal.pone.0035345
    [58] Zhang X, Zhu J, Xing R, et al. (2012) miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. Lung Cancer 77: 488-494. doi: 10.1016/j.lungcan.2012.05.107
    [59] Kraemer A, Barjaktarovic Z, Sarioglu H, et al. (2013) Cell survival following radiation exposure requires miR-525-3p mediated suppression of ARRB1 and TXN1. PLoS One 8: e77484. doi: 10.1371/journal.pone.0077484
    [60] Lerner AG, Upton JP, Praveen PV, et al. (2012) IRE1alpha induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Cell Metab 16: 250-264. doi: 10.1016/j.cmet.2012.07.007
    [61] Knoll S, Furst K, Kowtharapu B, et al. (2014) E2F1 induces miR-224/452 expression to drive EMT through TXNIP downregulation. EMBO Rep 15: 1315-1329. doi: 10.15252/embr.201439392
    [62] Ragusa M, Statello L, Maugeri M, et al. (2012) Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors. J Mol Med (Berl) 90: 1421-1438. doi: 10.1007/s00109-012-0918-8
    [63] Yan GR, Xu SH, Tan ZL, et al. (2011) Global identification of miR-373-regulated genes in breast cancer by quantitative proteomics. Proteomics 11: 912-920. doi: 10.1002/pmic.201000539
    [64] He HC, Zhu JG, Chen XB, et al. (2012) MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer. FEBS Lett 586: 2451-2458. doi: 10.1016/j.febslet.2012.06.003
    [65] Jiang W, Min J, Sui X, et al. (2014) MicroRNA-26a-5p and microRNA-23b-3p up-regulate peroxiredoxin III in acute myeloid leukemia. Leuk Lymphoma: 1-12.
    [66] Lee HK, Finniss S, Cazacu S, et al. (2014) Mesenchymal Stem Cells Deliver Exogenous miRNAs to Neural Cells and Induce Their Differentiation and Glutamate Transporter Expression. Stem Cells Dev 23: 2851-2861. doi: 10.1089/scd.2014.0146
    [67] Yang ZB, Zhang Z, Li TB, et al. (2014) Up-regulation of brain-enriched miR-107 promotes excitatory neurotoxicity through down-regulation of glutamate transporter-1 expression following ischaemic stroke. Clin Sci (Lond) 127: 679-689. doi: 10.1042/CS20140084
    [68] Morel L, Regan M, Higashimori H, et al. (2013) Neuronal exosomal miRNA-dependent translational regulation of astroglial glutamate transporter GLT1. J Biol Chem 288: 7105-7116. doi: 10.1074/jbc.M112.410944
    [69] Moon JM, Xu L, Giffard RG (2013) Inhibition of microRNA-181 reduces forebrain ischemia-induced neuronal loss. J Cereb Blood Flow Metab 33: 1976-1982. doi: 10.1038/jcbfm.2013.157
    [70] Kaalund SS, Veno MT, Bak M, et al. (2014) Aberrant expression of miR-218 and miR-204 in human mesial temporal lobe epilepsy and hippocampal sclerosis-Convergence on axonal guidance. Epilepsia 55: 2017-2027. doi: 10.1111/epi.12839
    [71] Fridovich I (1978) The biology of oxygen radicals. Science 201: 875-880. doi: 10.1126/science.210504
    [72] Lu M, Zhang Q, Deng M, et al. (2008) An analysis of human microRNA and disease associations. PLoS One 3: e3420. doi: 10.1371/journal.pone.0003420
    [73] Aoyama K, Watabe M, Nakaki T (2008) Regulation of neuronal glutathione synthesis. J Pharmacol Sci 108: 227-238. doi: 10.1254/jphs.08R01CR
    [74] Cooper AJ, Kristal BS (1997) Multiple roles of glutathione in the central nervous system. Biol Chem 378: 793-802.
    [75] Janaky R, Varga V, Hermann A, et al. (2000) Mechanisms of L-cysteine neurotoxicity. Neurochem Res 25: 1397-1405. doi: 10.1023/A:1007616817499
    [76] Quintana-Cabrera R, Fernandez-Fernandez S, Bobo-Jimenez V, et al. (2012) gamma-Glutamylcysteine detoxifies reactive oxygen species by acting as glutathione peroxidase-1 cofactor. Nat Commun 3: 718. doi: 10.1038/ncomms1722
    [77] Seelig GF, Simondsen RP, Meister A (1984) Reversible dissociation of gamma-glutamylcysteine synthetase into two subunits. J Biol Chem 259: 9345-9347.
    [78] Dalton TP, Chen Y, Schneider SN, et al. (2004) Genetically altered mice to evaluate glutathione homeostasis in health and disease. Free Radic Biol Med 37: 1511-1526. doi: 10.1016/j.freeradbiomed.2004.06.040
    [79] Yang Y, Dieter MZ, Chen Y, et al. (2002) Initial characterization of the glutamate-cysteine ligase modifier subunit Gclm(-/-) knockout mouse. Novel model system for a severely compromised oxidative stress response. J Biol Chem 277: 49446-49452.
    [80] Ristoff E, Larsson A (2007) Inborn errors in the metabolism of glutathione. Orphanet J Rare Dis 2: 1-9. doi: 10.1186/1750-1172-2-1
    [81] Brigelius-Flohe R, Maiorino M (2013) Glutathione peroxidases. Biochim Biophys Acta 1830: 3289-3303. doi: 10.1016/j.bbagen.2012.11.020
    [82] Kryukov GV, Castellano S, Novoselov SV, et al. (2003) Characterization of mammalian selenoproteomes. Science 300: 1439-1443. doi: 10.1126/science.1083516
    [83] Arthur JR (2000) The glutathione peroxidases. Cell Mol Life Sci 57: 1825-1835.
    [84] Power JH, Blumbergs PC (2009) Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Acta Neuropathol 117: 63-73. doi: 10.1007/s00401-008-0438-3
    [85] Muse KE, Oberley TD, Sempf JM, et al. (1994) Immunolocalization of antioxidant enzymes in adult hamster kidney. Histochem J 26: 734-753. doi: 10.1007/BF00158205
    [86] Li S, Yan T, Yang JQ, et al. (2000) The role of cellular glutathione peroxidase redox regulation in the suppression of tumor cell growth by manganese superoxide dismutase. Cancer Res 60: 3927-3939.
    [87] Knopp EA, Arndt TL, Eng KL, et al. (1999) Murine phospholipid hydroperoxide glutathione peroxidase: cDNA sequence, tissue expression, and mapping. Mamm Genome 10: 601-605. doi: 10.1007/s003359901053
    [88] Hall L, Williams K, Perry AC, et al. (1998) The majority of human glutathione peroxidase type 5 (GPX5) transcripts are incorrectly spliced: implications for the role of GPX5 in the male reproductive tract. Biochem J 333: 5-9.
    [89] Nguyen VD, Saaranen MJ, Karala AR, et al. (2011) Two endoplasmic reticulum PDI peroxidases increase the efficiency of the use of peroxide during disulfide bond formation. J Mol Biol 406: 503-515. doi: 10.1016/j.jmb.2010.12.039
    [90] Lindenau J, Noack H, Asayama K, et al. (1998) Enhanced cellular glutathione peroxidase immunoreactivity in activated astrocytes and in microglia during excitotoxin induced neurodegeneration. Glia 24: 252-256. doi: 10.1002/(SICI)1098-1136(199810)24:2<252::AID-GLIA10>3.0.CO;2-Z
    [91] Satoh J, Yamamoto Y, Asahina N, et al. (2014) RNA-Seq Data Mining: Downregulation of NeuroD6 Serves as a Possible Biomarker for Alzheimer's Disease Brains. Dis Markers 2014: 123165.
    [92] Deponte M (2013) Glutathione catalysis and the reaction mechanisms of glutathione-dependent enzymes. Biochim Biophys Acta 1830: 3217-3266. doi: 10.1016/j.bbagen.2012.09.018
    [93] Johnson JA, el Barbary A, Kornguth SE, et al. (1993) Glutathione S-transferase isoenzymes in ratbrain neurons and glia. J Neurosci 13: 2013-2023.
    [94] Martin HL, Teismann P (2009) Glutathione--a review on its role and significance in Parkinson's disease. FASEB J 23: 3263-3272. doi: 10.1096/fj.08-125443
    [95] Zeevalk GD, Razmpour R, Bernard LP (2008) Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother 62: 236-249. doi: 10.1016/j.biopha.2008.01.017
    [96] Holmgren A (1989) Thioredoxin and glutaredoxin systems. J Biol Chem 264: 13963-13966.
    [97] Kenchappa RS, Ravindranath V (2003) Glutaredoxin is essential for maintenance of brain mitochondrial complex I: studies with MPTP. FASEB J 17: 717-719.
    [98] Lovell MA, Xie C, Gabbita SP, et al. (2000) Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. Free Radic Biol Med 28: 418-427. doi: 10.1016/S0891-5849(99)00258-0
    [99] Yoshihara E, Masaki S, Matsuo Y, et al. (2014) Thioredoxin/Txnip: redoxisome, as a redox switch for the pathogenesis of diseases. Front Immunol 4: 514.
    [100] Dringen R, Pfeiffer B, Hamprecht B (1999) Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci 19: 562-569.
    [101] Shanker G, Allen JW, Mutkus LA, et al. (2001) The uptake of cysteine in cultured primary astrocytes and neurons. Brain Res 902: 156-163. doi: 10.1016/S0006-8993(01)02342-3
    [102] Chen Y, Swanson RA (2003) The glutamate transporters EAAT2 and EAAT3 mediate cysteine uptake in cortical neuron cultures. J Neurochem 84: 1332-1339. doi: 10.1046/j.1471-4159.2003.01630.x
    [103] Himi T, Ikeda M, Yasuhara T, et al. (2003) Role of neuronal glutamate transporter in the cysteine uptake and intracellular glutathione levels in cultured cortical neurons. J Neural Transm 110: 1337-1348. doi: 10.1007/s00702-003-0049-z
    [104] Kanai Y, Hediger MA (2003) The glutamate and neutral amino acid transporter family: physiological and pharmacological implications. Eur J Pharmacol 479: 237-247. doi: 10.1016/j.ejphar.2003.08.073
    [105] Maragakis NJ, Rothstein JD (2004) Glutamate transporters: animal models to neurologic disease. Neurobiol Dis 15: 461-473. doi: 10.1016/j.nbd.2003.12.007
    [106] Zerangue N, Kavanaugh MP (1996) Interaction of L-cysteine with a human excitatory amino acid transporter. J Physiol 493: 419-423. doi: 10.1113/jphysiol.1996.sp021393
    [107] Aoyama K, Suh SW, Hamby AM, et al. (2006) Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat Neurosci 9: 119-126. doi: 10.1038/nn1609
    [108] Lin CI, Orlov I, Ruggiero AM, et al. (2001) Modulation of the neuronal glutamate transporter EAAC1 by the interacting protein GTRAP3-18. Nature 410: 84-88. doi: 10.1038/35065084
    [109] Abdul-Ghani M, Gougeon PY, Prosser DC, et al. (2001) PRA isoforms are targeted to distinct membrane compartments. J Biol Chem 276: 6225-6233. doi: 10.1074/jbc.M009073200
    [110] Ruggiero AM, Liu Y, Vidensky S, et al. (2008) The endoplasmic reticulum exit of glutamate transporter is regulated by the inducible mammalian Yip6b/GTRAP3-18 protein. J Biol Chem 283: 6175-6183. doi: 10.1074/jbc.M701008200
    [111] Aoyama K, Wang F, Matsumura N, et al. (2012) Increased neuronal glutathione and neuroprotection in GTRAP3-18-deficient mice. Neurobiol Dis 45: 973-982. doi: 10.1016/j.nbd.2011.12.016
    [112] Andersen JK (2004) Oxidative stress in neurodegeneration: cause or consequence? Nat Med 10: S18-25. doi: 10.1038/nrn1434
    [113] Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766.
    [114] Maciotta S, Meregalli M, Torrente Y (2013) The involvement of microRNAs in neurodegenerative diseases. Front Cell Neurosci 7: 265.
    [115] Schipper HM, Maes OC, Chertkow HM, et al. (2007) MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul Syst Bio 1: 263-274.
    [116] Cogswell JP, Ward J, Taylor IA, et al. (2008) Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 14: 27-41.
    [117] Tanner CM, Goldman SM (1996) Epidemiology of Parkinson's disease. Neurol Clin 14: 317-335. doi: 10.1016/S0733-8619(05)70259-0
    [118] Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 : 2283-2301.
    [119] Baba M, Nakajo S, Tu PH, et al. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152: 879-884.
    [120] Kim J, Inoue K, Ishii J, et al. (2007) A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317: 1220-1224. doi: 10.1126/science.1140481
    [121] Gusella JF, MacDonald ME, Ambrose CM, et al. (1993) Molecular genetics of Huntington's disease. Arch Neurol 50: 1157-1163. doi: 10.1001/archneur.1993.00540110037003
    [122] Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57: 369-384. doi: 10.1097/00005072-199805000-00001
    [123] Novak MJ, Tabrizi SJ (2010) Huntington's disease. BMJ 340: c3109. doi: 10.1136/bmj.c3109
    [124] Browne SE, Ferrante RJ, Beal MF (1999) Oxidative stress in Huntington's disease. Brain Pathol 9: 147-163.
    [125] Petr GT, Bakradze E, Frederick NM, et al. (2013) Glutamate transporter expression and function in a striatal neuronal model of Huntington's disease. Neurochem Int 62: 973-981. doi: 10.1016/j.neuint.2013.02.026
    [126] Packer AN, Xing Y, Harper SQ, et al. (2008) The bifunctional microRNA miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J Neurosci 28: 14341-14346. doi: 10.1523/JNEUROSCI.2390-08.2008
    [127] Marti E, Pantano L, Banez-Coronel M, et al. (2010) A myriad of miRNA variants in control and Huntington's disease brain regions detected by massively parallel sequencing. Nucleic Acids Res 38: 7219-7235. doi: 10.1093/nar/gkq575
    [128] Mason RP, Casu M, Butler N, et al. (2013) Glutathione peroxidase activity is neuroprotective in models of Huntington's disease. Nat Genet 45: 1249-1254. doi: 10.1038/ng.2732
    [129] Kim C, Lee HC, Sung JJ (2014) Amyotrophic lateral sclerosis - cell based therapy and novel therapeutic development. Exp Neurobiol 23: 207-214. doi: 10.5607/en.2014.23.3.207
    [130] Sreedharan J, Brown RH, Jr. (2013) Amyotrophic lateral sclerosis: Problems and prospects. Ann Neurol 74: 309-316. doi: 10.1002/ana.24012
    [131] Synofzik M, Ronchi D, Keskin I, et al. (2012) Mutant superoxide dismutase-1 indistinguishable from wild-type causes ALS. Hum Mol Genet 21: 3568-3574. doi: 10.1093/hmg/dds188
    [132] Butovsky O, Siddiqui S, Gabriely G, et al. (2012) Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest 122: 3063-3087. doi: 10.1172/JCI62636
    [133] Koval ED, Shaner C, Zhang P, et al. (2013) Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum Mol Genet 22: 4127-4135. doi: 10.1093/hmg/ddt261
    [134] Baillet A, Chanteperdrix V, Trocme C, et al. (2010) The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson's disease. Neurochem Res 35: 1530-1537. doi: 10.1007/s11064-010-0212-5
    [135] Golenia A, Leskiewicz M, Regulska M, et al. (2014) Catalase activity in blood fractions of patients with sporadic ALS. Pharmacol Rep 66: 704-707. doi: 10.1016/j.pharep.2014.02.021
    [136] Sturm E, Stefanova N (2014) Multiple system atrophy: genetic or epigenetic? Exp Neurobiol 23: 277-291. doi: 10.5607/en.2014.23.4.277
    [137] Wenning GK, Tison F, Ben Shlomo Y, et al. (1997) Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 12: 133-147. doi: 10.1002/mds.870120203
    [138] Dallmann R, Brown SA, Gachon F (2014) Chronopharmacology: new insights and therapeutic implications. Annu Rev Pharmacol Toxicol 54: 339-361. doi: 10.1146/annurev-pharmtox-011613-135923
    [139] Bass J (2012) Circadian topology of metabolism. Nature 491: 348-356. doi: 10.1038/nature11704
    [140] Kondratov RV (2007) A role of the circadian system and circadian proteins in aging. Ageing Res Rev 6: 12-27. doi: 10.1016/j.arr.2007.02.003
    [141] Kondratov RV, Kondratova AA, Gorbacheva VY, et al. (2006) Early aging and age-related pathologies in mice deficient in BMAL1, the core componentof the circadian clock. Genes Dev 20: 1868-1873. doi: 10.1101/gad.1432206
    [142] Willison LD, Kudo T, Loh DH, et al. (2013) Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse model. Exp Neurol 243: 57-66. doi: 10.1016/j.expneurol.2013.01.014
    [143] Beaver LM, Klichko VI, Chow ES, et al. (2012) Circadian regulation of glutathione levels and biosynthesis in Drosophila melanogaster. PLoS One 7: e50454. doi: 10.1371/journal.pone.0050454
    [144] Xu YQ, Zhang D, Jin T, et al. (2012) Diurnal variation of hepatic antioxidant gene expression in mice. PLoS One 7: e44237. doi: 10.1371/journal.pone.0044237
    [145] Krishnan N, Davis AJ, Giebultowicz JM (2008) Circadian regulation of response to oxidative stress in Drosophila melanogaster. Biochem Biophys Res Commun 374: 299-303. doi: 10.1016/j.bbrc.2008.07.011
    [146] Pablos MI, Reiter RJ, Ortiz GG, et al. (1998) Rhythms of glutathione peroxidase and glutathione reductase in brain of chick and their inhibition by light. Neurochem Int 32: 69-75. doi: 10.1016/S0197-0186(97)00043-0
    [147] Filipski E, King VM, Etienne MC, et al. (2004) Persistent twenty-four hour changes in liver and bone marrow despite suprachiasmatic nuclei ablation in mice. Am J Physiol Regul Integr Comp Physiol 287: R844-851. doi: 10.1152/ajpregu.00085.2004
    [148] Arjona A, Sarkar DK (2005) Circadian oscillations of clock genes, cytolytic factors, and cytokines in rat NK cells. J Immunol 174: 7618-7624. doi: 10.4049/jimmunol.174.12.7618
    [149] Kochman LJ, Weber ET, Fornal CA, et al. (2006) Circadian variation in mouse hippocampal cell proliferation. Neurosci Lett 406: 256-259. doi: 10.1016/j.neulet.2006.07.058
    [150] Ma D, Panda S, Lin JD (2011) Temporal orchestration of circadian autophagy rhythm by C/EBPbeta. EMBO J 30: 4642-4651. doi: 10.1038/emboj.2011.322
    [151] Kondratova AA, Dubrovsky YV, Antoch MP, et al. (2010) Circadian clock proteins control adaptation to novel environment and memory formation. Aging (Albany NY) 2: 285-297.

  • This article has been cited by:

    1. Moshe Rosenberg, Yael Rosenberg, Proteolysis during aging of commercial full-fat and reduced-fat Cheddar cheeses of identical chronological age, 2022, 7, 2471-2086, 855, 10.3934/agrfood.2022052
  • Reader Comments
  • © 2015 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
AIMS Molecular Science
0.7

Metrics

Article views(7441) PDF downloads(1233) Cited by(13)

Preview PDF
Download XML
Export Citation
Article outline
Abstract
   Introduction
   Materials and methods
   Results and discussion
   Conclusions
Conflict of interest
Acknowledgments
References

Figures and Tables

Figures(1)  /  Tables(1)

Other Articles By Authors

Related pages

Tools

Copyright © AIMS Press

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog